- 期刊
- OpenAccess
新型序貫療法對難治性幽門螺旋菌感染的療效分析
An innovative sequential regimen for the eradication of refractory helicobacter pylori infection
摘要
目的：研究含N-乙酰半胱氨酸的21天序貫療法在難治性幽門螺旋菌感染（Helicobacter pylori, HP）的臨床應用價值。方法：連續性收集HP治療失敗患者，包括初治失敗及復治失敗者，給予含N-乙酰半胱氨酸的21天序貫療法治療，所有受試者於療程結束4週後行復檢（13C呼氣試驗檢測或大便HP抗原檢測）。結果：85名難治性HP感染患者經過21天序貫治療後的治癒率為77.6%（intention to treat, ITT）及90.4%（Per Protocol, PP），其中三次或以上復治失敗的挽救清除率可達80.9%（ITT）及94.4%（PP），未發現性別，年齡或復治次數對清除率有影響（P>0.05）。結論：含N-乙酰半胱氨酸的21天序貫方案在難治性幽門螺桿菌感染的治療中有理想效果。
並列摘要
Objective: To evaluate the efficacy of 21 days sequential regimen containing N-acetyl cysteine in the eradication of refractory Helicobacter pylori infection. Methods: This was a non randomized single center study, patients were included consecutively, in whom standard anti HP regimen or second line regimen had failed. 21 days sequential regimen was prescribed. Eradication rate was confirmed by 13C-urea breath test or HP antigen stool test. Results: Totally 85 patients were included and eradication rate was 77.6% in intention to treat (ITT) analysis and 90.4% in Per Protocol (PP) analysis. In sub-analysis, eradication rate of 80.1% (ITT) and 94.4% (PP) was gained respectively in patients who at least failed to two previous regimens. Variables studied, including gender, age and failure numbers, showed no association with the eradication rate (P>0.05). Conclusion: 21 days sequential regimen including N-acetyl cysteine is useful in the eradication of refractory helicobacter pylori infection.